Me: *stunned into silence* YES actually let me addend my note to say that right now
Them: Ok approved!
Me: *stunned into silence* YES actually let me addend my note to say that right now
Them: Ok approved!
(But also seriously after this year semaglutide is cooked, all the newer multi-agonists are so much better)
(But also seriously after this year semaglutide is cooked, all the newer multi-agonists are so much better)
It's just they're *that* far ahead of everyone else in the race for new GLP1/weight loss/diabetes medicines. Fully 40% of the drugs discussed in this article come *just* from one company.
That's unheard of in pharma spaces.
It's just they're *that* far ahead of everyone else in the race for new GLP1/weight loss/diabetes medicines. Fully 40% of the drugs discussed in this article come *just* from one company.
That's unheard of in pharma spaces.
Recognize any of these in your kitchen?
Soon the local pharmacies will have to stock more of it solely because of me 🤣
Soon the local pharmacies will have to stock more of it solely because of me 🤣
Like can we do that pretty please?
It's 2026, we have better drugs and at that point A1c goals are out the window anyways.
That is an absolute disaster waiting to happen.
Like can we do that pretty please?
It's 2026, we have better drugs and at that point A1c goals are out the window anyways.
That is an absolute disaster waiting to happen.
“AI is actually better than doctors at doing this,” said Dr. Adam Oskowitz, Doctronic co-founder and an associate professor of surgery at the University of California San Francisco
Tirzepatide + Taltz (an IL-17a MAB) significantly improved psoriatic arthritis symptoms and caused significant weight loss at the same time in data published this afternoon.
@rheumcat.bsky.social @mikejohansenmd.medsky.social
investor.lilly.com/news-release...
Tirzepatide + Taltz (an IL-17a MAB) significantly improved psoriatic arthritis symptoms and caused significant weight loss at the same time in data published this afternoon.
@rheumcat.bsky.social @mikejohansenmd.medsky.social
investor.lilly.com/news-release...
Same rules apply here with obesity treatments.
Same rules apply here with obesity treatments.
Yeah this guy!! I'm so excited to do this! Much GLP1 and glucagon myth busting along with breaking down stigmas around obesity!
Yeah this guy!! I'm so excited to do this! Much GLP1 and glucagon myth busting along with breaking down stigmas around obesity!
Reality is GLP1 medications will be #1 and #2 for sales in 2026 which IS remarkable.
Reality is GLP1 medications will be #1 and #2 for sales in 2026 which IS remarkable.
At some point this madness has to stop. What the hell else am I going to prescribe for a systemic allergic reaction?
At some point this madness has to stop. What the hell else am I going to prescribe for a systemic allergic reaction?